ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1750
+0.0350 (+1.11%)
As of 12:36PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.1400
Open3.1300
Bid3.2000 x 800
Ask3.2100 x 1400
Day's Range3.0600 - 3.2499
52 Week Range2.2700 - 29.7500
Volume535,484
Avg. Volume1,304,123
Market Cap152.743M
Beta (3Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Acorda Provides Update for Second Quarter Ended June 30, 2019

    ARDSLEY, N.Y.-- -- INBRIJA™ 2Q 2019 net sales of $3.0 million CHMP issues positive opinion on INBRIJA AMPYRA ® 2Q 2019 net sales of $44.0 million Acorda Therapeutics, Inc. provided a financial and pipeline update for the quarter ended June 30, 2019. “We made significant progress on the launch of Inbrija during the second quarter. Effective May 24, 2019, Inbrija became preferred on the Express Scripts ...

  • Business Wire

    Acorda Receives Positive CHMP Opinion for INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (ACOR) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending INBRIJA’s approval by the European Commission (EC). The recommended indication is: Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (off episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. INBRIJA was approved by the U.S. Food and Drug Administration on December 21, 2018 for the intermittent treatment of OFF episodes (also known as OFF periods) in people with Parkinson’s disease treated with carbidopa/levodopa.

  • Business Wire

    Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled for August 1, 2019

    Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its second quarter 2019 update and financial results on Thursday, August 1 at 4:30 p.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

  • Business Wire

    Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress

    Acorda Therapeutics, Inc. (ACOR) today announced that it will debut an art gallery inspired by people with Parkinson’s (PwP) at the 5th World Parkinson Congress (WPC) in Kyoto, Japan. The six pieces of art, ranging from acrylic sculptures to oil paintings, are the centerpiece of Acorda’s Framing OFF Through Art initiative. OFF periods are the re-emergence of Parkinson’s symptoms, and affect approximately 40 percent of the one million people living with Parkinson’s in the U.S. This initiative builds on Acorda’s “Live Well.

  • PR Newswire

    Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE

    LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare ...

  • Business Wire

    Acorda Therapeutics to Present at Jefferies 2019 Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in patients with Parkinson’s disease treated with carbidopa/levodopa.

  • Business Wire

    Acorda Provides Update for First Quarter Ended March 31, 2019

    ARDSLEY, N.Y.-- -- INBRIJA™ commercially available on February 28; first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA 1Q 2019 net sales of $1.3 million; approximately 2,000 prescription request forms received through April 2019 AMPYRA ® 1Q 2019 net sales of $40.1 million Acorda Therapeutics, Inc. provided ...

  • Business Wire

    Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019

    Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

  • Business Wire

    Acorda to Present New Long-Term Data for INBRIJA™ (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting

    Acorda Therapeutics, Inc. (ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa.

  • Business Wire

    Acorda Therapeutics Announces Management Changes

    Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months. “We thank Andrew for his many contributions to Acorda over the past five years. One of his first achievements was helping to lead Acorda’s acquisition of Civitas and INBRIJA, which was transformational for the Company,” said Ron Cohen, M.D., Acorda’s President and CEO.

  • Business Wire

    Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Oppenheimer & Co. Annual Healthcare Conference on Tuesday, March 19 at 1:35 p.m. EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.

  • GlobeNewswire

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)

    LOS ANGELES, March 05, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of Acorda Therapeutics, Inc. (NASDAQ: ACOR) investors concerning.

  • GlobeNewswire

    Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    Acorda Therapeutics Announces Commercial Launch of INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment in people with Parkinson’s taking carbidopa/levodopa who experience OFF episodes. “OFF periods are extremely disruptive for those living with Parkinson’s. We are excited that INBRIJA is now available to address this important unmet medical need, and that prescriptions are already being filled,” said Ron Cohen, M.D., Acorda’s President and CEO.

  • Business Wire

    Acorda Therapeutics to Present at Cowen Annual Health Care Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Cowen and Company Global Health Care Conference on Monday, March 11 at 1:30PM EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.

  • Business Wire

    Acorda Therapeutics to Present at Leerink Global Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.m. EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in patients with Parkinson’s disease treated with carbidopa/levodopa.

  • Business Wire

    Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018

    ARDSLEY, N.Y.-- -- INBRIJA™ approved December 21, 2018 – first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA commercially available in 1Q19 AMPYRA® 4Q18 net revenue of $64.2 million 2018 year-end cash, cash equivalents and investments of $445 million Acorda Therapeutics, Inc. provided financial and pipeline ...

  • Business Wire

    Acorda Appoints Peter S. Carbone Senior Vice President, Quality

    Acorda Therapeutics, Inc. (ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality. Mr. Carbone will report to Ron Cohen, M.D., President and CEO of Acorda and will be a member of the Company’s Leadership Team. In his role, Mr. Carbone will lead Acorda’s Quality Assurance and Quality Control departments and manage all company-wide quality initiatives, including the Quality Management System.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within Rexnord, Carlisle Companies, Acorda Therapeutics, Valmont Industries, Reliance Steel & Aluminum, and Thermo Fisher Scientific — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019

    Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

  • Business Wire

    Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (ACOR) today announced that The Lancet Neurology published results from SPAN℠-PD, the Phase 3 pivotal efficacy trial of INBRIJA™ (levodopa inhalation powder), also referred to as CVT-301. Multiple secondary endpoints were supportive of the primary endpoint.

  • Business Wire

    Acorda Provides 2018 Highlights and 2019 Guidance at J.P. Morgan Healthcare Conference

    Acorda Therapeutics, Inc. (ACOR) today provided 2018 highlights, 2019 guidance and commercialization plans for INBRIJA at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. “The approval of INBRIJA is a major milestone for Acorda. Burkhard Blank, M.D., Acorda’s Chief Medical Officer, added, “INBRIJA represents the first FDA approval of a treatment using the ARCUS® technology, a platform that allows delivery of relatively large doses of medication through inhalation.

  • ACCESSWIRE

    Biotech News Driving These Companies

    HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently. We are highlighting: Endonovo Therapeutics, ...

  • ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)
    Business Wire

    ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low levels of dopamine between doses of oral carbidopa/levodopa, the standard oral baseline Parkinson’s treatment. “Today’s approval of INBRIJA marks a major milestone for both Acorda and the Parkinson’s community, for whom we are gratified to have developed this much needed therapy,” said Ron Cohen, M.D., Acorda President and CEO.

  • Business Wire

    Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)

    Acorda Therapeutics, Inc. (ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low levels of dopamine between doses of oral carbidopa/levodopa, the standard oral baseline Parkinson’s treatment. “Today’s approval of INBRIJA marks a major milestone for both Acorda and the Parkinson’s community, for whom we are gratified to have developed this much needed therapy,” said Ron Cohen, M.D., Acorda President and CEO.